Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
small decrease » small increased (Expand Search)
Showing 1,581 - 1,600 results of 39,282 for search '(( significant ((disease increases) OR (small decrease)) ) OR ( significant decrease decrease ))', query time: 0.52s Refine Results
  1. 1581
    Experimental design.

    Experimental design. by Amy J. Schuh (8520354)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 1582
    Pre- and post-study virus-specific IgG responses for bats in the SOSV-MARV and KASV-MARV experimental cohorts.

    Pre- and post-study virus-specific IgG responses for bats in the SOSV-MARV and KASV-MARV experimental cohorts. by Amy J. Schuh (8520354)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 1583
    SOSV loads in specimens obtained from bats in the SOSV-MARV experimental cohort.

    SOSV loads in specimens obtained from bats in the SOSV-MARV experimental cohort. by Amy J. Schuh (8520354)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 1584
    KASV loads in specimens obtained from bats in the KASV-MARV experimental cohort.

    KASV loads in specimens obtained from bats in the KASV-MARV experimental cohort. by Amy J. Schuh (8520354)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 1585
    Weights and body temperatures of bats assigned to the SOSV-MARV and KASV-MARV experimental cohorts.

    Weights and body temperatures of bats assigned to the SOSV-MARV and KASV-MARV experimental cohorts. by Amy J. Schuh (8520354)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 1586
    Data used to generate Figs 2–7 and S1 Fig.

    Data used to generate Figs 2–7 and S1 Fig. by Amy J. Schuh (8520354)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 1587
    MARV shedding dynamics in bats from the SOSV-MARV experimental cohort.

    MARV shedding dynamics in bats from the SOSV-MARV experimental cohort. by Amy J. Schuh (8520354)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 1588
    Comparative Analysis of Chills Experience Across Three Groups: This table presents a detailed comparison of three groups (A, B, and C) in terms of their experiences with chills. It includes the number of participants in each group, frequency, intensity, and duration of chills, along with demographics such as gender, age, race, education level, and income. Statistical significance (p-value) is also provided for each category.

    Comparative Analysis of Chills Experience Across Three Groups: This table presents a detailed comparison of three groups (A, B, and C) in terms of their experiences with chills. It... by Felix Alexandre Schoeller (20988295)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 1589
    Two-way ANCOVA results for Task 1. The bold values highlight statistically significant results of Task 1.

    Two-way ANCOVA results for Task 1. The bold values highlight statistically significant results of Task 1. by Mucahit Gemici (21519313)

    Published 2025
    Save to List
    Saved in:
  10. 1590
    One-way ANCOVA results for Task 2. The bold values highlight statistically significant results of Task 2.

    One-way ANCOVA results for Task 2. The bold values highlight statistically significant results of Task 2. by Mucahit Gemici (21519313)

    Published 2025
    Save to List
    Saved in:
  11. 1591
    CRFS significant scores and contributions.

    CRFS significant scores and contributions. by Bo Yu (241082)

    Published 2025
    Save to List
    Saved in:
  12. 1592
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 1593
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 1594
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 1595
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 1596
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 1597
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 1598
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 1599
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 1600
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: